Repligen Corp
repligen.comRepligen Corp (NASDAQ: RGEN) is a bioprocessing equipment and consumables company that makes products used in the manufacturing of biological drugs. It generates revenue by selling systems, single-use consumables, and instruments to biopharmaceutical manufacturers across upstream and downstream drug production processes. Repligen operates as a single bioprocessing business segment organized into four product franchises: Filtration (including Fluid Management), Chromatography, Process Analytics, and Proteins. The company has built its portfolio through internal development and targeted acquisitions since 2012, accumulating over 40 years of industry history. Corporate headquarters are in Waltham, Massachusetts, with 19 manufacturing sites, the majority in the United States, and additional sites in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan. The filing notes historical reliance on a limited number of large customers as a material revenue risk. Repligen does not pay dividends based on the filing's risk and capital structure disclosures.
Products & Services
Filtration: XCell ATF Cell Retention Systems, KrosFlo TFF tangential flow filtration systems, hollow fiber filter consumables, ProConnex fluid management flowpaths, bags, tubing, valves, totes, carts, and mixers (including ProConnex MixOne RG-X launched 2025). Chromatography: OPUS Pre-Packed Columns (single-use, resin-agnostic), KRM Chromatography Systems. Process Analytics: PATsmart SoloVPE and SoloVPE PLUS slope spectroscopy systems (launched 2025), PATsmart FlowVPX inline concentration measurement systems. Proteins franchise also disclosed but not detailed in excerpts.
Revenue Model
Product revenue from selling bioprocessing systems, single-use consumables, and instruments to biopharmaceutical manufacturers. Revenue is transactional, with an installed-base consumables component tied to systems sold.
Customers & Markets
Biopharmaceutical and biological drug manufacturers using upstream and downstream bioprocessing. End markets include process development, clinical-scale manufacturing, and commercial-scale biological drug production. Filing discloses historical reliance on a limited number of large customers as a material concentration risk.
Geographic Exposure
Headquarters in Waltham, Massachusetts. Manufacturing in the United States (California, Massachusetts, New Hampshire, New Jersey, New York) and internationally in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan. Filing notes foreign currency exchange rate exposure as a material risk.
Loading...
